Paradoxical Skin Reaction in a Patient with Crohn's Disease Infliximab Treatment
Larissa Starling de A. Fernandes*, Daniela Martinez,
Omar Lupi, Ricardo Barbosa Lima, Carlos José Martins, Antonio D`Acri
Gaffree e Guinle University Hospital - Federal University of
State of Rio de Janeiro (UNIRIO), Rua Mariz e Barros, Tijuca, Brazil
*Corresponding author: Larissa Starling de A. Fernandes, Gaffree e
Guinle University Hospital - Federal University of State of Rio de Janeiro
(UNIRIO), Avenida Hildebrandode Araujo Goes 55, Brazil, Tel: +5521992007083,
EMail: starling_larissa@hotmail.com
Received Date: 21 March 2017; Accepted Date: 21 April, 2017; Published
Date: 27 April, 2017
Citation: Fernandes LSA, Martinez D, Lupi O, Lima RB, Martins CJ,
D`Acri A (2017) Paradoxical Skin Reaction in a Patient with Crohn's Disease
Infliximab Treatment. Clin Exp Dermatol Ther: J119. DOI:
10.29011/2575-8268/100019
1. Introduction
The anti-TNF-α, including adalimumab and infliximab, are drugs
that have dramatically improved the prognosis of inflammatory bowel disease.
However, some concerns have recently emerged on anti-TNF alpha induced
inflammatory skin lesions, such as psoriasiform and eczematiform, lichenoid
eruptions and lupus-erythematosus-skin-like. Other rare complications included
neutrophilic dermatoses such as amicrobial pustulosis, which resembles the
inverted psoriasis. All of these skin disorders represent a paradoxical
reaction, especially the psoriasiform pattern, since anti-TNF- α therapies are
commonly used for psoriasis treatment. Paradoxical psoriasis is a relevant side
effect of anti-TNF-α therapy with an incidence rate of 5 per 100 person-years
[1-3]. We report the case of a patient with Crohn's Disease (CD) treated with
infliximab who presented extensive psoriasiform skin lesions, inverse
psoriasis-like.
2. Case Report
A 56-year-old woman was referred for evaluation of
desquamation involving her face, neck and scalp during the previous week.
Her past medical history revealed that she had been diagnosed with CD ten years
previously, with gastric, duodenal, distal ileum, cecum, colon and, at the
present time, intense perianal involvement. She did not have any personal or
familial history of psoriasis. She had been treated with mesalazine,
azathioprine and adalimumabe, that was replaced to infliximab (5mg⁄kg intravenously)
with control of CD. Two years after infliximab introduction, after the 9th
infusion, the eruption got worse with severe pruritus and extensive
erythematous, scaly and exudative patches on the face, scalp and neck. There
was progression to the flexural areas on the trunk and limbs. The nail plates
were normal (Figure 1). Skin lesions became clearly psoriasiform coincidentally
with an increase in the frequency of infliximab infusions (every 6 weeks).
Histopathological examination showed psoriasiform hyperplasia with marked
parakeratosis, spongiosis exocytosis and necrotic keratinocyte. Skin lesions
became clearly psoriasiform coincidentally with an increase in the frequency of
infliximab infusions (every 6 weeks). The inicial clinical diagnostic hypothesis
were contact dermatitis, atopic dermatitis, seborrheic dermatitis and inverse
psoriasis. Histopathological examinationof a skin biopsy taken from her neck,
close to the hairline, showed psoriasiform hyperplasia with marked
parakeratosis, spongiosis exocytosis, superficial inflammatory infiltrate
consisting of lymphocytes, eosinophils and necrotic keratinocytes (Figure 2).
Results of laboratory tests were within normal limits. The clinical and
histopathological findings, and the history of infliximab therapy led to the
diagnosis of a paradoxical skin reaction inverse psoriasis-like. The treatment
was started with topical betamethasone dipropionate, oral prednisone 20mg/day
and oral acitretin 20mg/day. After discussing the case with the
gastroenterologist, infliximab therapy was discontinued and there was slowly
resolution of cutaneous lesion in 4 months. During this period skin directed
therapy was progressively reduced (Figure 3). The improvement of the eruption
after stopping infliximab reinforce the role of the antiTNF as a trigger for
this reaction. For the CD the patient remains using mesalazine and
azathioprine. Vedolimumab was added to the therapy regimen to replace
infliximab.
The paradoxical induction of psoriasis-like eruption under
anti-TNF-α treatments was first reported by Verea et al in 2004. These side
effects, in particular psoriasis, have been defined “paradoxical”, because
anti-TNF-α are commonly used to treat wild psoriasis. The time between the
introduction of the medication and the appearance of lesions can range from a
few days to many months [1-7]. The main risk factors are female sex, CD,
personal or family history of inflammatory skin diseases, smoking, treatment
with adalimumab [2].
The triggering of inverse psoriasis as a paradoxical side effect
to treatment with infliximab for Crohn's disease has been reported in the
literature.
Sometimes is difficult to diagnose this paradoxical reaction at
the first visit. In this case our first hypothesis were contacted and
seborrheic dermatitis. We suspected that the eruption was a paradoxical
reaction to infliximab because it was severely itchy, resembled inverse
psoriasis and was refractory to treatment with topical corticosteroids and low
dose oral prednisone. So, a biopsy was performed revealing a spongiotic and
psoriasiform dermatitis with some elements that suggest a drug reaction such as
the presence of necrotic keratinocytes in the epidermis and eosinophils and
melanophages in the papilar dermis indicating basal layer damage.
Our patient denied any treatment of drugs associated with the
development of psoriasis, such as beta-blockers, lithium, antimalarials,
angiotensin-converting enzyme inhibitors, tetracyclines or nonsteroidal
anti-inflammatory agents. Also, she denied symptoms of bacterial or viral
infection preceding the beginning of the eruption and the results of the
laboratory tests were within normal limits.
Another element that strongly suggest the role of infliximab as
a trigger was the improvement of the eruption after it was stopped.
The pathogenesis has not been fully understood, but it seems
that imbalance between different cytokines and activated inflammatory pathways
can cause the onset and/or the aggravation of these skin lesions. Regarding
anti-TNF- α induced psoriasis, it has been speculated that the inhibition of
induced psoriasis, it has been speculated that the inhibition of TNF-α by
antibody drugs may stimulate uncontrolled production IFN-γ by plasmacytoid
dendritic cells, inducing the recruitment of T cells and the secretion of
pro-inflammatory cytokines IL12/23, thereby inducing paradoxical reactions or
psoriasis. The combination therapy with anti-TNF-α plus immunosuppressants is
associated with a reduced risk of paradoxical psoriasis [1-7].
In case of development of suggestive psoriasiform lesions, a
dermatology evaluation with eventual biopsy is mandatory. When patients need a
maintenance therapy for the inflammatory bowel disease (IBD), a switch to a
different anti-TNF-α or to an immunosuppressant, such as cyclosporine, methotrexate,
could be attempted, according to the intestinal activity and the previous drug
history. The suspension of the anti-TNF drug associated with the start of
systemic medication for psoriasis resulted in higher cure rates: approximately
64% versus 44% when systemic medications started without suspension of the
immunobiological agent. A systematic review of 222 patients with IBD treated
with anti-TNF-α, with paradoxical reaction showed that most were adult women,
with CD treated with infliximab. This review indicated that the psoriasiform
reactions were more prevalent than the typical psoriasis [1,3,9].
With this case report, we aim to illustrate a peculiar type of
psoriasiform reaction to infliximab inverse psoriasis-like. It was difficult to
diagnose at first time and with the increasing use of anti-TNF-α in the
treatment of inflammatory and autoimmune diseases, these reactions will be more
common and dermatologists should be aware of the clinical and histopathological
aspects of them.
Figure 1: (a) erythematous, scaly patches, some with erosions and exudate located at (a) frontal, periorbital and perinasal, perioral, (b) periauricular (c) retroauricular and cervical areas.
Figure 2: Histopathological examination showed (a) psoriasiform hyperplasia with marked parakeratosis, spongiosis, exocytosis, (b) necrotic keratinocyte (arrow), (c) melanophages and (d) eosinophils. HE, original magnification (a) 100x (b-c) 200x (c) 400x.
Figure 3: (a) Regression of lesions at (a) periauricular, (b) neck, (c) periumbilical area, (d) infra-abdominal fold.
- Denadai R, Teixeira FV, Steinwurz F, Romiti R,
Saad-Hossne R (2013) Induction or exacerbation of psoriatic lesions during
anti-TNF-α therapy for inflammatory bowel disease: A systematic literature
review based on 222 cases. J Crohn’s Colitis 7:517-524.
- Pugliese D, Guidi L, Ferraro PM, Marzo M, Felice
C et al. (2015) Paradoxical psoriasis in a large cohort of patients
with inflammatory bowel disease receiving treatment with anti-TNF alpha:
5-year follow-up study. Aliment Pharmacol Ther 42: 880-888.
- Seneschal J, Milpied B, Vergier B, Lepreux S,
Schaeverbeke T, et al, (2009) Cytokine imbalance with increased production
of interferon-a in psoriasiform eruptions associated with antitumour
necrosis factor-a treatments. British J Dermatol 161:1081-1088.
- Peramiquel L, Puig L, Dalmau J, Ricart E, Roe E, et
al, (2005) Onset of flexural psoriasis during infliximab treatment for
Crohn's disease. Clin Exp Dermatol 30:713-714.
- Marzano AV, Tavecchio S, Berti E, Gelmetti C, CugnoM
(2015) Paradoxical Autoinflammatory Skin Reaction to Tumor Necrosis Factor
Alpha Blockers Manifesting as Amicrobial Pustulosis of the Folds in
Patients with Inflammatory Bowel Diseases. Medicine (Baltimore) 94: 1818.
- Coutzac C, Chapuis J, Poullenot F, Chabrun E,
Capdepont M, et al, (2015) Association Between Infliximab Trough Levels
and the Occurrence of anifestations in Patients with Inflammatory Bowel
Disease: a Case-Control Study. J Crohns Colitis 9: 982-987.
- Verea MM, Pozo DJ, Yebra-Pimentel MT (2004)
Psoriasiform eruption induced by infliximab. The Annals of Pharmacotherapy
8: 54-57.
- Omland SH, Gniadecki R (2015) Psoriasis inversa: A
separate identity or a variant of psoriasis vulgaris? Clin Dermatol 33:
456-461.
- Vasconcelos JB, Pereira DN, Vargas TJS, Levy RA,
Pinheiro GRC, et al, (2016) Paradoxical psoriasis after the use of
anti-TNF in a patient with rheumatoid arthritis. An Bras Dermatol. 91:
S137-139.